Pfizer Halts Twice Daily Obesity Pill Trial

Published on December 1, 2023

Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients dropped out of a mid-stage trial with high rates of side effects such as nausea and vomiting. While Pfizer will now focus on a…

Read Full Article (External Site)